(NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced ...

Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ:BPTH), a biotechnology company ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

Bio-Path Holdings ( (BPTH) ) has released its Q3 earnings. Here is a breakdown of the information Bio-Path Holdings presented ...

Department of Medicinal Chemistry, College of Pharmacy, University of Utah, 2000 East 30 South Skaggs 306, Salt Lake City, Utah 84112, United States ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable anti-cancer antisense ... vehicle for nucleic acid therapeutics added ...

A company that is working on advancing non-viral delivery technologies for nucleic acid therapeutics, such as mRNA, small interfering ribonucleic acid (siRNA), and antisense oligonucleotides (ASOs ...

“The innovative use of extracellular vesicles as a delivery vehicle for nucleic acid therapeutics added a potentially powerful treatment modality for treating malignancies. The ability to ...

TMDU researchers demonstrate proof of concept of antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. A new preclinical model offers a unique ...